Characteristic | T1c: whole cohort [cases (%)] | T1c: Matched cohort [cases (%)] | ||||
---|---|---|---|---|---|---|
Chemotherapy | P-value | Chemotherapy | P-value | |||
No | Yes | No | Yes | |||
GRADE | < 0.01 | 0.64 | ||||
I | 9648 (32.86%) | 836 (7.77%) | 777 (11.42%) | 802 (11.79%) | ||
II | 15,475 (52.70%) | 3823 (35.55%) | 3028 (44.52%) | 2979 (43.80%) | ||
III | 4239 (14.44%) | 6094 (56.67%) | 2997 (44.06%) | 3021 (44.41%) | ||
SURGERY | < 0.01 | 0.61 | ||||
Breast-conserving | 19,489 (66.37%) | 6389 (59.42%) | 3956 (58.16%) | 3974 (58.42%) | ||
Total mastectomy | 7640 (26.02%) | 3379 (31.42%) | 2174 (31.96%) | 2190 (32.20%) | ||
Modified radical mastectomy | 2233 (7.61%) | 985 (9.16%) | 672 (9.88%) | 638 (9.38%) | ||
RADIATION | 0.96 | 0.41 | ||||
No | 12,848 (43.76%) | 4708 (43.78%) | 3307 (48.62%) | 3259 (47.91%) | ||
Yes | 16,514 (56.24%) | 6045 (56.22%) | 3495 (51.38%) | 3543 (52.09%) | ||
SUBTYPE | < 0.01 | 0.93 | ||||
HoR + /HER2- | 26,924 (91.70%) | 4984 (46.35%) | 4579 (67.32%) | 4579 (67.32%) | ||
HoR + /HER2 + | 973 (3.31%) | 2324 (21.61%) | 873 (12.83%) | 891 (13.10%) | ||
HoR-/HER2 + | 256 ( 0.87%) | 769 (7.15%) | 246 ( 3.62%) | 250 (3.68%) | ||
HoR-/HER2- | 1209 (4.12%) | 2676 (24.89%) | 1104 (16.23%) | 1082 (15.91%) | ||
AGE (year) | < 0.01 | 0.76 | ||||
< 60 | 10,350 (35.25%) | 6891 (64.08%) | 3645 (53.59%) | 3663 (53.85%) | ||
≥ 60 | 19,012 (64.75%) | 3862 (35.92%) | 3157 (46.41%) | 3139 (46.15%) |